Skip to content

Clinical Study on the Efficacy of Intermittent Theta Burst Stimulation of the Contralesional PMd Region in Promoting Functional Recovery of Moderate to Severe Upper Limb Hemiplegia

Clinical Study on the Efficacy of Intermittent Theta Burst Stimulation of the Contralesional PMd Region in Promoting Functional Recovery of Moderate to Severe Upper Limb Hemiplegia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118152
Enrollment
Unknown
Registered
2026-02-02
Start date
2025-03-14
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

cM1 group:Intervention of the cM1 by ITBS
False Stimulus Group:Intervention of the cM1 by false ITBS
cPMd group:Intervention of the cPMd by ITBS

Sponsors

Shanghai Second Rehabilitation Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.The diagnosis conforms to the "Key Points for Diagnosis of Major Cerebrovascular Diseases in China 2019" standards and is confirmed by head CT or MRI; 2.First occurrence of unilateral cerebral hemisphere infarction/hemorrhage, and the patient with hemorrhage has never undergone head surgery; 3.Age is 55-85 years old; 4.Disease course is 3-12 months; 5.Moderate to severe motor function impairment exists, with the proximal part of the FMA-UE score on the hemiplegic side < 26 points, and poor response to conventional neuroregulation; 6.The patient or their immediate family members understand and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with unstable conditions and vital signs; 2.Patients who cannot tolerate iTBS treatment; 3.Patients with a history of Parkinson's disease, peripheral neuropathy, and other conditions that can cause motor dysfunction; 4.Patients with concurrent tumors, severe respiratory, cardiac, hepatic, renal, endocrine and hematopoietic system diseases, etc; 5.Pregnant and lactating women; 6.Patients with a history of epilepsy or a family history of epilepsy, those with metal pacemakers in the body, metal implants in the brain, cochlear implants, and skull defects, etc., who are not suitable for transcranial magnetic stimulation treatment; 7.Patients currently participating in other clinical trials or those who have recently received neuromodulation treatment;

Design outcomes

Primary

MeasureTime frame
Functional Near Infrared (fNIRS) Detection;

Secondary

MeasureTime frame
Fugl-Meyer Assessment-Upper Extremity;

Countries

China

Contacts

Public ContactCheng Xie

Shanghai Second Rehabilitation Hospital

xieencheng1993@126.com+86 21 6618 1108

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026